CDXS vs. SCLX, GOSS, HOWL, OVID, ELEV, NKTR, MASS, CMPX, PIII, and ATOS
Should you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Scilex (SCLX), Gossamer Bio (GOSS), Werewolf Therapeutics (HOWL), Ovid Therapeutics (OVID), Elevation Oncology (ELEV), Nektar Therapeutics (NKTR), 908 Devices (MASS), Compass Therapeutics (CMPX), P3 Health Partners (PIII), and Atossa Therapeutics (ATOS). These companies are all part of the "medical" sector.
Scilex (NASDAQ:SCLX) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends.
Scilex has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Codexis has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500.
Codexis received 340 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 61.14% of users gave Codexis an outperform vote.
Codexis has higher revenue and earnings than Scilex. Codexis is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.
69.7% of Scilex shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 8.7% of Scilex shares are owned by company insiders. Comparatively, 6.3% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Codexis has a net margin of -108.69% compared to Codexis' net margin of -244.60%. Codexis' return on equity of 0.00% beat Scilex's return on equity.
Scilex currently has a consensus price target of $8.00, indicating a potential upside of 583.76%. Codexis has a consensus price target of $6.80, indicating a potential upside of 146.38%. Given Codexis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Scilex is more favorable than Codexis.
In the previous week, Scilex had 1 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Scilex and 3 mentions for Codexis. Scilex's average media sentiment score of 0.41 beat Codexis' score of 0.00 indicating that Codexis is being referred to more favorably in the news media.
Summary
Codexis beats Scilex on 10 of the 18 factors compared between the two stocks.
Get Codexis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
